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Treatment discontinuation remains the single most important and 
potentially preventable risk factor for stent thrombosis.(7)
New risk factors for steNt thrombosis           
In order to appreciate the effects of variant alleles of the cyto-
chrome P-450 system, the pharmacokinetics and pharmacoge-
netics of clopidogrel are reviewed. 
Clopidogrel pharmacokinetics and the P-450 enzyme system
Most drugs are dependent on the cytochrome P-450 enzymes for 
their metabolism and elimination and many require bioactivation to 
form the active compound. Figure 1 summarises the nomenclature 
of the cytochrome P-450 system.
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iNtroductioN                                                              
Stent thrombosis is a catastrophic complication of percutaneous 
coronary intervention (PCI) and is associated with a mortality of 
between 25 to 40%. Various trials report the frequency of stent 
thrombosis as (0.8-2%).(1,2) Most evaluations however come from 
registries that are likely to underestimate the real prevalence.(3) 
The perception that stent thrombosis is very low in all patients 
has resulted in a lack of adherence to professional guidelines.(4) 
New data to identify patients at increased risk for stent throm- 
bosis are emerging. The COURAGE and FAME trials should 
have tempered over-exuberant PCI, and hopefully now the inter-
ventionalists will also be proactive in seeking out the patient at 
higher risk for stent thrombosis. Numerous risk factors for stent 
thrombosis have been established (Table 1).(5,6)
stent thrombosis is a catastrophic complication of percu-
taneous coronary intervention (Pci) and is associated with 
a mortality of 25 to 40%. the perception that stent throm-
bosis is very low in all patients has resulted in a lack of 
adherence to professional guidelines. New data to identify 
patients at increased risk for stent thrombosis are emerging. 
clopidogrel is a prodrug and the activation of clopidogrel is 
dependent on cY2c19. Numerous alleles of cYP2c19 exist. 
the allele cYP2cP*2 has been associated with a marked 
decrease in platelet responsiveness to clopidogrel. heter-
ozygote carriers of the cYP2c19*2 have a 2.7 fold increased 
risk and homozygotes a 4.8 fold increased risk of stent 
thrombosis. Prospective randomised clinical trials will be 
necessary to determine the efficacy of cYP2c19 genotype-
directed therapy in evidence-based clinical decision making. 
Point-of-care platelet-function tests are becoming avail- 
able and some centres are now performing such tests on 
their Pci patients. the most recent aha/acc/scai guide-
lines recommend testing for clopidogrel responsiveness in 
patients at high risk of sub acute stent thrombosis and 
recommend increasing the dose of clopidogrel in non-
responders. SAHeart 2010; 7:150-153
tabLe 1:  Established risk factors for stent thrombosis
Treatment discontinuation  Stent malpositioning
Active smoking  Poor stent apposition
Diabetes  Recent MI 
Bifurcations  Cancer
Small arteries  Renal failure
Low TIMI flow  Heart failure
Increased stent length  Chronic inflammatory diseases
Stent type  Polymer type



















A simplified diagram of some CYP-450 enzymes relevant to 
cardiologists is reviewed in Table 2. 
Three of the many enzymes evolved in drug metabolism are 
highlighted. CYP2C19 is important in the elimination of proton 
pump inhibitors (PPIs) and statins but activates the prodrug 
clopidogrel. CYP3A4/5 metabolises many drugs. CYP3A4/5 is 
inhibited by grapefruit juice which would result in slower elimina-
tion of affected drugs. CYP2C9 is important in warfarin meta- 
bolism and elimination.
Clopidogrel is a prodrug. After absorption 85% is converted into 
an inactive form by esterases. Only 15% is then available for 
conversion to its active metabolite. This conversion process is 
complex and involves numerous enzymes. CYP2C19 in particular 
is required at two separate oxidative steps (Figure 2).
Eighty-five percent of absorbed clopidogrel is converted into an 
inactive form by esterases. Only 15% is then available for conversion 
to its active metabolite. Clopidogrel activation is dependent on 
CYP2C19 as it is involved in both of the hepatic oxidative steps.
Basic pharmacogenetics of clopidogrel
Numerous alleles of CYP2C19 exist. The allele CYP2CP*2 has 
been associated with a loss of function which results in a marked 
decrease in platelet responsiveness to clopidogrel.(8) The presence 
of genetically poorly functioning CYP2C19*2 has been shown to 
effect clopidogrel activation, especially when it is present in the 
homozygous state (CYP2C19*2/*2).(9)
The FAST-MI study demonstrated an association between stent 
thrombosis and CYP2C19*/*. The TRITON TIMI 38 study demon-
strated an association between stent thrombosis CYP2C19* and 
CYP2C19*/*.(10,11)
A recent collaborative meta-analysis involving 9 studies presented 
at the American Heart Association in November 2009 by Mega, 
revealed that heterozygote carriers of the CYP2C19*2, had a 
2.7-fold increased risk and homozygotes a 4.8-fold increased risk 
of stent thrombosis. In this meta-analysis, 26% of the population 
were heterozygous carriers of the variant allele and 2% were 
homozygous carriers.
FIGURE 1: Nomenclature of the cytochrome P-450 Enzyme System 
(CYP). CYP-450 enzymes are designated with the abbreviation 
(CYP), followed by an Arabic numeral indicating the family, a capital 
letter indicating the subfamily and another numeral for the 
individual enzyme. The convention is to italicise the name when 
referring to the gene. For example, CYP2C19 is the gene that 
encodes the enzyme CYP2C19. 








tabLe 2:  CYP-450 enzymes relevant to cardiologists
CYP2C19  Activates:  Clopidogrel
 Metabolises:  PPIs, statins
CYP3A4/5  Metabolises many drugs:
 Lipid soluble statins, calcium channel blockers,   
 Amiodarone, PPIs, sildenafil, macrolides
CYP2C9  Metabolises:  Warfarin














Prasugrel (a third generation thienopyridine) does not have the 
same reliance on CYP2C19 as clopidogrel. In a predefined sub-
group analysis of the TRITON-TIMI 38, clinical outcomes of patients 
on prasugrel were not affected by CYP2C19 polymorphisms. In 
particular, there was less stent thrombosis. Prasugrel recently 
received FDA approval based on results of the TRITON-TIMI 38 
study.(12) These benefits were, in part, offset by a higher risk of 
bleeding in prasugrel-treated patients. However an increased 
bleeding risk did not occur if certain groups were excluded. This 
subgroup analysis included patients with a history of stroke, age 
>75 years and those with a body weight of less than 60 kg.
Ticagrelor is a reversible oral P2Y12 receptor antagonist in a new 
chemical class of anti-platelet agents termed cyclopentyl-triazolo-
pyrimidines that does not require metabolic conversion to an active 
form. The PLATO trial demonstrated that ticagrelor achieved a 
statistically significant reduction in the primary efficacy endpoint 
(cardiovascular death, myocardial infarction or stroke) compared 
to clopidogrel.(13)
Prasugrel and ticagrelor are not yet available in South Africa. This 
poses the question if we should  be testing for CYP2C19* in 
patients on clopidogrel then. Prospective randomised clinical trials 
will be necessary to determine the efficacy of CYP2C19 genotype-
directed therapy in evidence-based clinical decision-making. Rapid 
genetic testing for the CYP2C19*2 variant is not available but is 
being developed.
Drug interactions
PPIs are metabolised by CYP2C19 and may therefore compete 
for CYP2C19 when used in conjunction with clopidogrel.
There have been numerous observational studies which suggest 
that the clopidogrel and PPI interaction can lead to adverse cardio-
vascular outcomes(14) (Figure 3). Omeprazole, in particular, has 
been incriminated while pantoprazole has reputedly less interaction 
with PPIs.(15) In the subgroup analyses of the CREDO and TRITON 
trials(16,17) no interaction was found. Preliminary analysis of data 
from the COGENT trial, a trial dedicated to specifically examining 
clopidogrel with a PPI vs placebo, failed to suggest a negative inter-
action. There is therefore conflicting evidence, but as some concern 
still exists prescribers should avoid the use of PPIs if possible. On 
November 17, 2009, the FDA updated the clopidogrel label with 
new warnings on omeprazole and other drugs that inhibit the 
CYP2C19 enzyme that could interact with clopidogrel. 
High on-treatment platelet reactivity
There are consistent data that patients who have persistently 
increased platelet reactivity despite clopidogrel therapy have an 
increased risk of ischaemic events. Recent findings have shown that 
a considerable number of patients who are resistant to clopidogrel 
may also be resistant to aspirin, which further increase their risk of 
stent thrombosis.(18)
Should we be measuring platelet function in patients who are 
taking clopidogrel after stent implantation? Should the dose of 
clopidogrel be increased in patients resistant to standard doses? 
It is interesting that the recently presented CURRENT OASIS-7 
study (presented at the European Society of Cardiology 2009) 
revealed that a loading dose of 600mg together with a higher 
maintenance dose of clopidogrel (150mg for one week after PCI) 
was associated with less stent thrombosis. There was no increased 
risk of bleeding when the TIMI major bleeding criteria were used. 
There was however a small increased risk of red cell transfusion.
Point-of-care platelet-function tests are becoming available and 
some centres are now performing such tests on their PCI patients. 
Unfortunately, there is no evidence that modifying the treatment of 
a hypo-responsive patient improves outcomes. Numerous trials 
are being conducted in this regard:
GRAVITAS (Gauging Responsiveness with a Verify Now Assay-
Impact on Thrombosis and Safety) trial, randomising patients 
deemed non-responsive to clopidogrel on point-of-care testing 
to receive higher dosing of clopidogrel.(19)
■
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fiGure 3: PPIs are metabolised by CYP2C19. CYP2C19 also 
activates clopidogrel. The theoretical potential for an adverse inter-



























TRIGGER PCI is assessing the efficacy of prasugrel versus 
clopidogrel for the reduction of adverse cardiovascular out-
comes in drug-eluting stent (DES) patients with high platelet 
reactivity on clopidogrel, using the Verify Now test. 
ARCTIC double randomisation of a monitoring adjusted anti-
platelet treatment versus a common anti-platelet treatment 
for DES-implantation and interruption versus continuation of 
double anti-platelet therapy.
coNcLusioN                                                                   
The most recent AHA/ACC/SCAI guidelines recommend testing 
for clopidogrel responsiveness in patients at high risk of sub-acute 
stent thrombosis and recommend increasing the dose of clopido-
grel in non-responders. The United Kingdom’s National Institute for 
Health and Clinical Excellence (NICE) has issued its provisional 
guidance on the use of prasugrel. The guidelines include patients 
undergoing primary PCI for ST-segment elevation MI, subsequent 
to stent thrombosis having occurred on clopidogrel treatment and 
in patients with diabetes mellitus.(20)
In France prasugrel is not available but compassionate usage has 
been increasing (Montalescot - personal communication).
Prasugrel and ticagrelor are not yet available in South Africa, so 
what should we do? 
A conservative approach would be to initially accept the 
results of the CURRENT OASIS-7 study and double the 
loading dose of clopidogrel to 600mg and increase the main-
tenance dose of clopidogrel to 150mg for one week, while 
waiting for the results of the randomised trials. 
A more proactive approach would be to measure platelet 
function and increase the dose of clopidogrel in non-responders 
and if there is no improvement in response, consider obtaining 
compassionate use of prasugrel. 
It should be emphasised however, that when stent thrombosis has 
occurred on clopidogrel treatment, serious consideration should 
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